1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Sedation - Pipeline Review, H1 2017

Sedation - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 54 pages

Sedation - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sedation – Pipeline Review, H1 2017, provides an overview of the Sedation (Central Nervous System) pipeline landscape.

Sedation is the depression of irritability or agitation. Symptoms include talk slowly and may slur their speech, unable to concentrate, feel dizzy, slow breathing, heart rate, blood pressure will be lower. Treatment includes barbiturates and benzodiazepines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sedation – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sedation (Central Nervous System)
Number of Products under Development for Sedation, H1 2017 7Number of Products under Development by Companies, H1 2017 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sedation (Central Nervous System) pipeline guide
Number of Products under Development for Sedation, H1 2017 7Number of Products under Development by Companies, H1 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes,
Number of Products under Development for Sedation, H1 2017 7Number of Products under Development by Companies, H1 2017

Sedation (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is
Number of Products under Development for Sedation, H1 2017 7Number of Products under Development by Companies, H1 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sedation (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Sedation (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sedation (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sedation (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sedation (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sedation (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sedation (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Sedation - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Sedation - Overview
Sedation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sedation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sedation - Companies Involved in Therapeutics Development
Drawbridge Pharmaceuticals Pty Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Nhwa Pharmaceutical Corp Ltd
NanoMedex Pharmaceuticals Inc
Paion AG
Primex Pharmaceuticals Oy
The Medicines Company
Therakind Ltd
Sedation - Drug Profiles
alphaxalone - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
clonidine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
EL-001 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
MDCO-700 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
midazolam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
propofol microemulsion - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
remimazolam - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
remimazolam - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule to Agonize GABA-A for Sedation - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
XK-568b - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Sedation - Dormant Projects
Sedation - Discontinued Products
Sedation - Product Development Milestones
Featured News and Press Releases
Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
Oct 05, 2016: Primex Files for Marketing Authorization for a paediatric sedative medication
Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting
Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China
Sep 01, 2016: Primex Announces Phase II Results of ADV6209 at the 16th World Congress of Anaesthesiologists
Aug 31, 2016: Primex Pharmaceuticals: Next real innovation in paediatric anesthesiasince propofol
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy
Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy
Feb 12, 2016: Paion: US-Patent and Trademark Office Grants Substance Patent For Remimazolam Besylate
Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment
Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy
Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority PMDA About Production Of Remimazolam For Japan
Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia
Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy
May 04, 2015: Drawbridge Pharmaceuticals Moves Phaxan Forward
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Sedation, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Sedation - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2017
Sedation - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Sedation - Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H1 2017
Sedation - Pipeline by NanoMedex Pharmaceuticals Inc, H1 2017
Sedation - Pipeline by Paion AG, H1 2017
Sedation - Pipeline by Primex Pharmaceuticals Oy, H1 2017
Sedation - Pipeline by The Medicines Company, H1 2017
Sedation - Pipeline by Therakind Ltd, H1 2017
Sedation - Dormant Projects, H1 2017
Sedation - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Sedation, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.